Indian pharmaceutical company Cipla Limited (BSE:500087) (NSE:CIPLA-EQ) and its US subsidiary Cipla USA Inc announced on Thursday that the US Food and Drug Administration (FDA) has given final approval for the Abbreviated New Drug Application (ANDA) for Albuterol Sulfate Inhalation Aerosol, 90 mcg per actuation.
Cipla said that the product is the first AB–rated generic therapeutic equivalent of Ventolin HFA, marketed by GlaxoSmithKline.
Albuterol Sulfate Inhalation Aerosol is indicated for the treatment or prevention of bronchospasm in adult and paediatric patients aged four years and older with reversible obstructive airway disease, as well as for the prevention of exercise-induced bronchospasm in patients aged four years and older.
According to IQVIA, the total US albuterol market is valued at approximately USD1.5bn.
This approval enhances Cipla's US respiratory portfolio, with approved generics for both Ventolin HFA and Proventil HFA.
Grünenthal completes Nociceptin Receptor (NOP) Agonist Phase I trial
United Therapeutics wins FDA approval for LungFX ex vivo lung perfusion device
bioMérieux files FDA application for rapid vaginitis diagnostic panel
Racura Oncology doses first patient in Phase 1 lung cancer trial
EU approves Cenrifki for secondary progressive multiple sclerosis without relapses
Oxford BioTherapeutics reports progress in Boehringer Ingelheim partnered programmes
Genprex receives Canadian Patent Allowance for Reqorsa gene therapy combination in lung cancer
Transgene expands myvac platform into non-small cell lung cancer with TG4070
Airiver Medical treats first chronic rhinosinusitis patient in Drug Coated Balloon clinical study
Precigen and the RRPF recognise International RRP Awareness Day
Guardant Health expands FDA-approved companion diagnostic use for HERNEXEOS
GSK to acquire Nuvalent for USD10.6bn to expand lung cancer portfolio